Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin and Imatinib in ALK+ ALCL
NCT02462538Phase 2Terminated
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- Nov 2015
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin, imatinib in Anaplastic Large Cell Lymphoma ALK-positive, sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Started Nov 2015; status: terminated.
02
Drugs
brentuximab vedotinimatinib
03
Conditions
Anaplastic Large Cell Lymphoma ALK-positive
Beyond the preview
Go deeper on NCT02462538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462538.